Akari Therapeutics (AKTX) Total Non-Current Liabilities (2011 - 2025)

Akari Therapeutics has disclosed Total Non-Current Liabilities across 10 years of filings, most recently posting $19.3 million for Q4 2025.

• Total Non-Current Liabilities for Q4 2025 came in at $19.3 million, down 30.83% year-over-year; the trailing twelve-month figure through Dec 2025 was $19.3 million (down 30.83% YoY), and the FY2025 annual result was $19.3 million, down 30.83% from the prior year.
• Total Non-Current Liabilities came in at $19.3 million for Q4 2025 at Akari Therapeutics, down from $22.6 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $28.9 million in Q1 2025 to a low of $4.5 million in Q4 2023.
• The 4-year median for Total Non-Current Liabilities is $15.6 million (2022), against an average of $16.5 million.
• Across the five-year window, Total Non-Current Liabilities sank 62.45% in 2023 and surged 523.33% in 2024, its largest moves.
• Akari Therapeutics' Total Non-Current Liabilities stood at $11.9 million in 2022, then tumbled by 62.45% to $4.5 million in 2023, then soared by 523.33% to $28.0 million in 2024, then slumped by 30.83% to $19.3 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $19.3 million (Q4 2025), $22.6 million (Q3 2025), and $25.2 million (Q2 2025), per Business Quant data.